Drugs / SAFIMESTOMIG
SAFIMESTOMIG
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05448599 | Jul 2022 → Jun 2024 | acute myeloid leukemia, myelodysplastic syndrome | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05048160 | Sep 2021 → Jun 2024 | cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05440045 | Sep 2022 → Jan 2024 | clear cell renal carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05446688 | Sep 2022 → Mar 2024 | lymphoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05431569 | Jul → Dec 2022 | lung cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAFIMESTOMIG | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068290 ↗ |
| Known as | 6MW3211 | “A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm” NCT05048160 ↗ |
| Known as | 6MW3211 injection | “6MW3211 injection” NCT05440045 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068290 ↗ |
| Route | Intravenous | “the intended dosing frequency is every 2 weeks (Q2W), IV.” NCT05048160 ↗ |